Merck's COVID-19 Drug Posts Poor Data; No Change to FVE
Merck’s updated analysis for its coronavirus treatment, molnupiravir, could aid Pfizer’s COVID-19 treatment, Paxlovid.
Merck’s updated analysis for its coronavirus treatment, molnupiravir, could aid Pfizer’s COVID-19 treatment, Paxlovid.
Merck’s (MRK) updated analysis showing less efficacy with coronavirus treatment molnupiravir doesn’t impact our fair value estimate. The reduced efficacy on preventing death or hospitalization of 30% (down from 48% on the interim analysis) will likely reduce the sales potential of the drug, especially with Pfizer’s (PFE) COVID-19 treatment Paxlovid showing almost 90% efficacy. However, we didn’t change our fair value estimate when we added molnupiravir sales to the Merck discounted cash flow model because the sales are split with partner Ridgeback, and because we expect sales to fall off quickly regardless of efficacy as the pandemic recedes with increased vaccine utilization. Despite the limited impact on Merck’s fair value estimate, the quick speed to market of molnupiravir reinforces the strong innovation power at Merck, which is a core element in the firm’s wide moat.
From a competitive perspective, the falling efficacy of molnupiravir is an additional positive for Pfizer’s Paxlovid. We think it is unlikely Pfizer’s final data from its Paxlovid study will follow a similar pattern of reduced efficacy in the final readout, and the lower efficacy from molnupiravir gives Paxlovid increased likelihood of market leadership. Further, if the new omicron COVID-19 variant is elusive to current vaccines, we would likely increase our sales projections for molnupiravir and Paxlovid, but the impact would likely be more meaningful for Pfizer, which doesn’t split the economics with a partner and would likely gain most of the upside.
Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days. |
Damien Conover does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.